DeCure's autonomous Cardio AI scientist is researching a drug-repurposing hypothesis for hypertrophic cardiomyopathy 26 — screening already-approved drugs against its 4-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleHypertrophic cardiomyopathy 26 maps to a 4-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for hypertrophic cardiomyopathy 26 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
hemoglobin subunit beta (HBB) — HBB is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet hemdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 1DXT · 1.7 Å · ligand PROTOPORPHYRIN IX CONTAINING FE (HEM). Experimental structure, not a prediction.
What the evidence adds up to
The 2024 Brazilian guidelines summarise that scientific knowledge of hypertrophic cardiomyopathy has improved, with a better understanding of pathogenesis, advances in imaging, and more common genetic analysis. The guidelines note the development of new medications that address molecular mechanisms linked to the pathophysiology. No specific drugs, survival data, or response rates are given in that abstract.
A 1996 review states that no therapies have been proven to improve prognosis in hypertrophic cardiomyopathy, and that there are few randomised trials of symptomatic treatment. The major drugs available for symptomatic therapy are listed as beta-blockers, calcium antagonists, and disopyramide. The abstract does not report any numerical outcomes from these drugs.
A 2023 scoping review describes hypertrophic cardiomyopathy as a condition characterised by left ventricular hypertrophy and diastolic dysfunction, with a risk of sudden cardiac death. It states that the causes include genetic mutations and mitochondrial dysfunction, but that the precise relationship between these factors remains unclear. The review aims to investigate this association but provides no trial results, survival figures, or response rates.
What is still missing are large randomised controlled trials that test any drug against placebo for hard outcomes such as mortality or hospitalisation. The 2024 guidelines mention new molecular medications, but no efficacy data from those drugs are reported in these abstracts. Patient stratification by genotype or mitochondrial function is not yet validated for guiding treatment.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Arquivos Brasileiros de Cardiologia · 2024 · 24 citations · open access
Guidelines on the Diagnosis and Treatment of Hypertrophic Cardiomyopathy - 2024
Abstract1. Introduction Scientific knowledge of hypertrophic cardiomyopathy (HCM) has significantly improved in the past decades. A better understanding of its pathogenesis, significant advances in the use of imaging methods, and the more common application of genetic analysis, in addition to a better characterization of the natural history of this myocardial disease, have profoundly reformulated its clinical and prognostic significance. Conversely, these processes were accompanied by the development of new medications addressing molecular mechanisms intrinsically linked to the pathophysiology and pathogenesis [...]
Medical, Surgical, and Interventional Management of Hypertrophic Cardiomyopathy
AbstractHypertrophic cardiomyopathy is a common but underrecognized cardiac disorder characterized by a heterogenous phenotype that includes increased left ventricular thickness, outflow obstruction, diastolic dysfunction, and arrhythmia. Hypertrophic cardiomyopathy is often heritable and associated with pathogenic variants in sarcomeric genes. While not curable, an integrated approach involving medical, interventional, and surgical care can have a considerable impact on disease burden, quality of life, and mortality. This review provides a practical overview of important topics in hypertrophic cardiomyopathy, including evaluation of differential diagnosis, imaging, provocation of left ventricular outflow obstruction, treatment of obstructive and nonobstructive hypertrophic cardiomyopathy with negative inotropic therapy and myosin inhibition, as well as surgical and interventional approaches to septal reduction and mitral valve intervention.
The American Journal of Managed Care · 2021 · 6 citations · open access
Hypertrophic cardiomyopathy: diagnosis and therapeutic options
AbstractHypertrophic cardiomyopathy is an underdiagnosed genetic disorder, resulting from mutations in sarcomeric proteins. It has a highly variable clinical presentation, with some individuals remaining asymptomatic and others having significant limitation of functional status. The disorder is typically characterized by left ventricular hypertrophy that is not explained by another cause. Patients are further classified based on whether there is obstruction of the left ventricular outflow tract. To-date, there are no pharmacologic therapies that alter the natural history of the disease. Therapeutic approaches have instead focused on symptom relief and prevention of sudden cardiac death. Newer therapies under investigation represent potential means to improve limiting symptoms.
Medical Therapy for Symptomatic Patients with Hypertrophic Cardiomyopathy
AbstractHypertrophic cardiomyopathy is a relatively uncommon myocardial disease with a heterogeneous presentation and complex pathophysiology. The condition is often asymptomatic; when symptoms are present, however, they are usually multiple, and each has several potential mechanisms. No therapies have been proven to improve prognosis, and there are few randomized trials of symptomatic treatment. Within these limitations, an approach to assessing the symptomatic patient is presented. The major drugs available for symptomatic therapy, namely beta-blockers, calcium antagonists and disopyramide, are reviewed. An overall management plan and a step-by-step strategy for the treatment of the symptomatic patient are presented.
Genetic Mutations and Mitochondrial Dysfunction as Modulating Factors in Hypertrophic Cardiomyopathy: An Updated Scoping Review
AbstractHypertrophic cardiomyopathy (HCM) is a cardiac condition characterized by left ventricular hypertrophy and diastolic dysfunction, posing a risk of sudden cardiac death. The causes of HCM are diverse, including genetic mutations and mitochondrial dysfunction, but the precise relationship between these factors remains unclear. This project focuses on investigating this association, as understanding the early mechanisms of HCM is crucial for the development of effective therapies, aiming to contribute to future advances in the treatment of this cardiac condition.
Hypertrophic obstructive cardiomyopathy and the mitral valve
AbstractHypertrophic cardiomyopathy (HCM) is a complex congenital cardiac disease and belongs to the group of cardiomyopathies. The estimated prevalence is 1:500. Although it has unique pathophysiological characteristics, there is a great diversity of functional, clinical, morphological, and molecular findings. Therefore and because of the relatively low prevalence in general practice, therapy management decisions have been derived from nonrandomized and retrospective investigations.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
